

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Prostate Cancer

First Guideline Development Group (GDG) meeting

9th & 10th February 2012

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

ATTENDEES:

GDG Members	
Mr Sean Duffy (SD)	Prof Howard Kynaston (HK)
Dr Peter Kirkbride (PK)	Brian McGlynn (BM)
Hugh Butcher (HB)	Dr Jonathan Oxley (JO)
Dr Sarah Cant (SC) (<i>left after agenda item 4 on day 2</i>)	Kathleen Nuttall (KN)
Prof Peter Hoskin (PH)	Dr Jonathan Richenberg (JR)
Nicola James (NJ)	
NCC-C staff	
Angela Bennett (AB) (<i>during agenda items 8-9 of day 1 and all day 2</i>)	Elise Hasler (EH)
Dr Nathan Bromham (NB)	Matthew Prettyjohns (MP)
Dr Andrew Champion (AC) (<i>during agenda items 1-6 of day 1 and all day 2</i>)	Victoria Titshall (VT)
Dr John Graham (JG) (<i>during agenda items 1-6 of day 1 and all day 2</i>)	
NICE staff	
Barbara Meredith (BM) (<i>during agenda items 1-7 of day 1 only</i>)	Claire Turner (CT) (<i>during agenda items 1-6 of day 1 only</i>)
Apologies	
Prof David Neal (DN)	

REPORT OF DISCUSSIONS AT THE MEETING

1 Welcome and apologies

SD welcomed everyone to the 1st meeting of the Prostate Cancer GDG and thanked the GDG members for volunteering for the group. Each member of the group introduced themselves and gave a background to where they are from and what they do.

Apologies for absence were received from Prof David Neal.

2 Declarations of interest

SD gave a brief overview of the NICE conflict of interest policy to the group and noted that some GDG members had already declared interests in their applications. These were as follows:

- SC declared that she is employed by the Prostate Cancer Charity which receives sponsorship from Astellas Pharma Europe Ltd., AstraZeneca UK Ltd., GlaxoSmithKline UK Ltd., Ipsen Ltd., Janssen, Novartis Pharmaceuticals UK Ltd., Sanofi-Aventis, Takeda UK Ltd. This interest was categorised as non-personal pecuniary specific.
- DN declared that he advises International Health Technology on appropriate tests to be used prostate cancer screening for employees of companies providing

Web minutes of 1st Prostate Cancer GDG meeting on 9th & 10th February 2012

private healthcare cover. This interest was categorised as personal pecuniary non-specific.

- DN declared that he led a bid to carry out an audit of prostate cancer management, with a tender to be put out shortly. This interest was categorised as non-personal pecuniary specific.
- DN declared that he co-chairs the Prostate Cancer Advisory Group. This interest was categorised as personal non-pecuniary.

No new interests were declared at the meeting. The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

4 Discussion

The GDG were given an introduction to NICE and its guideline development methodology.

The GDG discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO question for each topic.

The GDG discussed topics which were potential priorities for economic investigation.

5 Close of meeting

SD thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Tuesday 3rd April 2012**, starting at 10.45 in the Board Room, NCC-C Offices, Greyfriars Road, Cardiff and closed the meeting.